Experience

Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics

May 19, 2025

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Navya Dasari
Associate, New York
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Rick Jantz
Associate, Santa Monica
Steve Przesmicki
Partner, San Diego
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
David Burns
Special Counsel, Washington, DC
Eileen Marshall
Partner, Washington, DC
Jonathan Rivinus
Partner, Colorado

Related Practices & Industries

Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA

April 8, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Caroline Vu
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Marc Suskin
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Rebecca Ross
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Jiqiang Lin
Associate, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma

March 9, 2025

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Read more

Related contacts

Bill Roegge
Partner, New York
Kevin Cooper
Partner, New York
Marc Recht
Partner, Boston
Wesley Dietrich
Associate, Washington, DC
Kathryn Benvenuti
Associate, New York
Michael Bergmann
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Alan W. Tamarelli
Partner, New York
Julia R. Brinton
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Stella Sarma
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Karun Ahuja
Special Counsel, Chicago
Matthew Choy
Associate, New York
Jameson Davis
Associate, Boston
Kyle Hess
Associate, New York
Allison Kutner
Associate, New York
Breanna Qin
Associate, Palo Alto
Arda Can Tekin
Associate, New York
Ryan Vann
Partner, Chicago

Related Practices & Industries

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

December 3, 2024

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
David Burns
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Partner, Brussels

Related Practices & Industries

View more

Admissions and credentials

Massachusetts

New York

Pennsylvania

Rankings and accolades

Legal 500 US: Recommended for Commercial Deals and Contracts (2018)

Legal 500 US: Recommended for Technology Transactions (2018)